Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone

Abstract

Resistance to second-line tuberculosis drugs for patients with multidrug-resistant tuberculosis has emerged globally and is a potential risk factor for unfavorable outcomes of shorter duration drug regimens. We assessed the proportion of patients eligible for a shorter drug regimen in Uttar Pradesh, India, which had the highest rate of multidrug-resistant tuberculosis in India.

Keywords

• shorter regimen
• multidrug-resistant tuberculosis
• MDR TB
• tuberculosis
• TB
• tuberculosis and other mycobacteria